TY - JOUR
T1 - Statin therapy and the risk of osteoporotic fractures in patients with metabolic syndrome
T2 - A nested case-control study
AU - Kim, Kyoung Jin
AU - Choi, Jimi
AU - Kim, Ji Yoon
AU - Bae, Jae Hyun
AU - Kim, Kyeong Jin
AU - Kim, Hee Young
AU - Yoo, Hye Jin
AU - Seo, Ji A
AU - Kim, Nan Hee
AU - Choi, Kyung Mook
AU - Baik, Sei-Hyun
AU - Kim, Sin Gon
AU - Kim, Nam Hoon
N1 - Funding Information:
This study was supported by the big data analysis grant from The Korean Society of Lipid and Atherosclerosis.
Publisher Copyright:
© 2021 The Korean Society of Lipid and Atherosclerosis.
PY - 2021/9
Y1 - 2021/9
N2 - Objective: We aimed to investigate the association between statin use and the risk of major osteoporotic fractures in patients with metabolic syndrome (MetS). Methods: A nested case-control study was performed in patients with MetS (≥50 years) who had no history of osteoporotic fracture using the Korean National Health Insurance Service-Health Screening Cohort. This study included 17,041 patients diagnosed with new-onset osteoporotic fractures and controls matched in a 1:1 ratio by age, sex, body mass index, cohort entry date, and follow-up duration. Conditional logistic regression analysis was used to evaluate covariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Results: During a 4-year follow-up period, the risk of major osteoporotic fractures was significantly reduced by 9% (OR, 0.91; 95% CI, 0.85–0.97) in statin users compared with that in non-users. Among subtypes of major osteoporotic fracture, a risk reduction with statin therapy was significant for vertebral fracture (OR, 0.86; 95% CI, 0.79–0.94) but not for non-vertebral fracture (OR, 0.97; 95% CI, 0.88–1.06). Longer duration (OR, 0.97; 95% CI, 0.96–0.99, per 1-year increase) and higher cumulative dose (OR, 0.97; 95% CI, 0.95–0.99, per 365 defined daily doses) of statins were negatively associated with the risk of major osteoporotic fracture. Conclusion: This study supports the hypothesis that statin therapy has a beneficial effect on major osteoporotic fractures, especially vertebral fractures, in patients with MetS.
AB - Objective: We aimed to investigate the association between statin use and the risk of major osteoporotic fractures in patients with metabolic syndrome (MetS). Methods: A nested case-control study was performed in patients with MetS (≥50 years) who had no history of osteoporotic fracture using the Korean National Health Insurance Service-Health Screening Cohort. This study included 17,041 patients diagnosed with new-onset osteoporotic fractures and controls matched in a 1:1 ratio by age, sex, body mass index, cohort entry date, and follow-up duration. Conditional logistic regression analysis was used to evaluate covariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Results: During a 4-year follow-up period, the risk of major osteoporotic fractures was significantly reduced by 9% (OR, 0.91; 95% CI, 0.85–0.97) in statin users compared with that in non-users. Among subtypes of major osteoporotic fracture, a risk reduction with statin therapy was significant for vertebral fracture (OR, 0.86; 95% CI, 0.79–0.94) but not for non-vertebral fracture (OR, 0.97; 95% CI, 0.88–1.06). Longer duration (OR, 0.97; 95% CI, 0.96–0.99, per 1-year increase) and higher cumulative dose (OR, 0.97; 95% CI, 0.95–0.99, per 365 defined daily doses) of statins were negatively associated with the risk of major osteoporotic fracture. Conclusion: This study supports the hypothesis that statin therapy has a beneficial effect on major osteoporotic fractures, especially vertebral fractures, in patients with MetS.
KW - Case-control studies
KW - HMG-CoA reductase inhibitor
KW - Metabolic syndrome
KW - Osteoporotic fractures
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=85118141152&partnerID=8YFLogxK
U2 - 10.12997/JLA.2021.10.3.322
DO - 10.12997/JLA.2021.10.3.322
M3 - Article
AN - SCOPUS:85118141152
VL - 10
SP - 322
EP - 333
JO - Journal of Lipid and Atherosclerosis
JF - Journal of Lipid and Atherosclerosis
SN - 2287-2892
IS - 3
ER -